A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered intravascularly to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. Systemic administration of this agent provides a preferred route over previous disclosure of local direct administration. The same therapeutic agent can be effectively employed in the treatment of benign conditions, including benign prostatic hypertrophy and arteriosclerosis.

The University of Virginia Patent Foundation

Utilization of osteocalcin promoter to deliver therapeutic genes to tumors

In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy

The present invention provides a novel method of treating localized solid tumors and papilloma in an individual. The method comprises introducing a recombinant adenoviral vector containing the herpes simplex virus-thymidine kinase gene. Subsequently, a prodrug, such as the drug ganciclovir, is administered to the individual. The methods of the present invention may be used to treat several different types of cancers and papillomas, including colon carcinoma, prostate cancer, breast cancer, lung cancer, melanoma, hepatoma, brain and head and neck cancer.

thymidine/karcinóm prsníka

Utilization of osteocalcin promoter to deliver therapeutic genes to tumors

In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy

Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Najkompletnejšia databáza liečivých bylín podporovaná vedou